Navigation Links
BioMarin to Present at the Barclays Capital Global Healthcare Conference
Date:3/17/2010

e Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU; GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA and BMN 195, which is currently in Phase I clinical development for the treatment of Duchenne Muscular Dystrophy. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMarins Chief Executive Jean-Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times
2. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
3. BioMarin to Present at the Morgan Stanley Healthcare Conference
4. BioMarin to Present at the Baird Healthcare Conference
5. BioMarin to Present at the Jefferies Healthcare Conference
6. BioMarin to Present at the Goldman Sachs Healthcare Conference
7. BioMarin to Present at the Deutsche Bank Health Care Conference
8. BioMarin to Present at the Baird Growth Stock Conference
9. BioMarin Announces First Quarter 2009 Financial Results
10. BioMarin to Host First Quarter 2009 Financial Results Conference Call and Webcast on Thursday, April 30 at 5:00 p.m. ET (23:00 CET)
11. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015 ... biological drugs to treat cancer, viral infections and ... Sir John Bell , the Regius Professor ... the Office for the Strategic Coordination of Health ... effect.      (Photo: http://photos.prnewswire.com/prnh/20150330/736483 ...
(Date:3/30/2015)... and MADISON, Wis. , March ... Nakajima ,) (TSE: 4901) ("Fujifilm") and Cellular Dynamics International, ... ICEL ) ("CDI"), a leading developer and manufacturer of ... specifications, today announced that the two companies have entered ... via an all-cash tender offer to be followed by ...
(Date:3/29/2015)... Texas , March 29, 2015 /PRNewswire/ ... presentation of important study data showing the ... in 1,599 gynecologic cancer samples. Using Caris ... profiling service, researchers identified expression of programmed ... cancers independent of histology while its ligand ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The consumption ... back of the recession and high prices in 2008. ... has recovered and keeps on gaining momentum now. , ... stands at more than 100,000 thousand tonnes. No considerable ... Meantime, the global capacity rocketed during 2012-2013, registering 11% ...
Breaking Biology Technology:Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3
... 27, 2008 - Vol. 299. No. 8: ,Venous Thromboembolism ... Administration for the Treatment of ... Biotech believes that,the conclusions of a study published in ... American Medical Association (JAMA) by Bennett, et al, do,not ...
... Colo., Feb. 26 Replidyne, Inc.,(Nasdaq: RDYN ) today ... ended December 31, 2007., Replidyne reported a net loss ... or a net loss per basic and diluted common share,of ... million, or $0.36 per,basic and diluted common share, for the ...
... Firms Recommend Pharmion ... merger with Celgene Special Meeting ... Corp. Urges All Shareholders to Vote FOR the Proposed Merger, ... ) today announced that Institutional Shareholder Services,(ISS) has recommended that ...
Cached Biology Technology:Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 2Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 3Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 4Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 5Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 6Replidyne Announces 2007 Fourth Quarter and Full Year Results 2Replidyne Announces 2007 Fourth Quarter and Full Year Results 3Replidyne Announces 2007 Fourth Quarter and Full Year Results 4Replidyne Announces 2007 Fourth Quarter and Full Year Results 5Replidyne Announces 2007 Fourth Quarter and Full Year Results 6Replidyne Announces 2007 Fourth Quarter and Full Year Results 7ISS Recommends Pharmion Shareholders Vote for Merger With Celgene 2ISS Recommends Pharmion Shareholders Vote for Merger With Celgene 3
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/48tj8z/global_biometrics ... "Global Biometrics Market Forecast and Opportunities, 2020" ... for biometric authentication systems is projected to grow ... The driving forces for this highly ... projects and constant development in technology. In 2014, ...
(Date:3/2/2015)... JOSE, Calif. , March 2, 2015 /PRNewswire/ ... the leading developer of human interface solutions, today ... technology that is designed to enable rapid and ... Natural ID™ module for gaming is a turnkey ... ODMs the ability to quickly integrate fingerprint ID ...
(Date:3/2/2015)... VILNIUS, Lithuania , March 2, 2015   ... AI technologies, today introduced the SentiGaze Software Development ... developers to create applications that use off-the-shelf webcams to ... a user gazes at a monitor. Heatmaps can be ... determining the effectiveness of online advertising. The SDK can ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... a new location or go extinct as a result of ... Northern England seem to defy the odds and adapt to ... study by scientists from Syracuse University and the University of ... of the Early Edition of the Proceedings of the ...
... -- The Soil Science Society of America (SSSA) applauds ... his colleagues in the Senate who helped usher in ... placing soil on par with water and air. ... Senators Kent Conrad (D-ND), Charles Grassley (R-IA), Russ Feingold ...
... lenses are joining the trend to go green. Chemical ... fluid found in our bodies can be used as a ... step up from the current wave of self-moisturizing contact lenses ... eye dryness and increase wearer comfort. It is estimated ...
Cached Biology News:New study finds that some plants can adapt to widespread climate change 2Senate resolution shines spotlight on the importance of soils 2Self-moisturizing contact lenses, naturally 2
ABI 432 Resins • Gln(Trt) Peptide Synthesis Column...
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
...
Human RUNX2/CBFA1 MAb (Clone 232902)...
Biology Products: